SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCAugust 4, 2026

L858R with a TP53 co-mutation halved real-world PFS on front-line osimertinib

Patients with advanced EGFR-mutant non-small cell lung cancer who carried both an L858R mutation and a TP53 co-mutation had less than half the median real-world progression-free survival on front-line osimertinib of patients carrying neither, and less than half the median overall survival, according to an analysis of 606 patients from a United States clinical-genomic database published in Lung Cancer. The authors describe it as the largest study to date evaluating EGFR subtype combined with TP53 co-mutation status on survival endpoints with front-line osimertinib.
Share

In brief

  • In 606 patients with advanced EGFR-mutant NSCLC treated with front-line osimertinib, median real-world progression-free survival was 10.1 months in those carrying both EGFR L858R and a TP53 co-mutation, against 21.4 months in those with an exon 19 deletion and wild-type TP53 (hazard ratio 2.2, P less than 0.001).
  • Median overall survival in the same comparison was 21.3 months against 53.4 months (hazard ratio 2.3, P less than 0.001).
  • Each marker predicted worse outcomes on its own: L858R against exon 19 deletion gave hazard ratios of 1.4 for real-world progression-free survival and 1.3 for overall survival; a TP53 co-mutation against wild-type gave 1.5 and 1.6.
  • TP53 co-mutations were present in 384 patients (63%) and L858R in 277 (46%); 186 patients (30.7%) carried both.
  • The patients were studied from a United States clinical-genomic database rather than enrolled in a trial, and progression-free survival is a real-world endpoint.

Study at a glance

  • Cohort: 606 patients studied from a United States clinical-genomic database
  • Population: Advanced EGFR-mutant non-small cell lung cancer receiving front-line osimertinib
  • Marker frequencies: L858R in 277 (46%), TP53 co-mutation in 384 (63%), both in 186 (30.7%)
  • Endpoints: Real-world progression-free survival and overall survival, by Kaplan-Meier methods
  • Both markers against neither, PFS: Median 10.1 against 21.4 months (hazard ratio 2.2, P less than 0.001)
  • Both markers against neither, survival: Median 21.3 against 53.4 months (hazard ratio 2.3, P less than 0.001)
  • Adjustment: Multivariable Cox regression accounting for relevant clinical covariates
  • Not reported in the abstract: Confidence intervals for any hazard ratio, and which covariates entered the multivariable models

Median real-world progression-free survival of 10.1 months with both markers against 21.4 with neither

The two-marker comparison is the central result. Patients whose tumours carried EGFR L858R together with a TP53 co-mutation had a median real-world progression-free survival of 10.1 months on front-line osimertinib. Patients whose tumours carried an exon 19 deletion and wild-type TP53 had a median of 21.4 months. The hazard ratio was 2.2, with a P value below 0.001.

The size of the group makes the comparison worth reading closely. Of the 606 patients, 186 (30.7%) carried both unfavourable alterations, so the group with the shorter survival is close to a third of the cohort rather than a rare subgroup. The endpoint is real-world progression-free survival, and the abstract does not state how progression was ascertained.

Median overall survival of 21.3 months against 53.4 months in the same patients

Overall survival separated by a wider absolute margin than progression-free survival. Median overall survival was 21.3 months in patients with both markers and 53.4 months in patients with neither, a hazard ratio of 2.3 with a P value below 0.001. The difference of just over 32 months is larger than the whole median survival of the two-marker group.

An overall survival difference observed in a database cohort carries whatever treatment patients received after osimertinib as well as the markers being studied, and the abstract reports no subsequent-therapy data. What the figures establish is the survival of these patients as observed, not the share of it attributable to the markers themselves.

“Having EGFR L858R or a TP53 co-mutation were independent predictors of inferior rwPFS and OS with front-line osimertinib.”Kim et al., Lung Cancer (2026)

Hazard ratios of 1.4 and 1.5 for each marker taken on its own

Taken separately, L858R against exon 19 deletion gave a hazard ratio of 1.4 for real-world progression-free survival (P equal to 0.001) and 1.3 for overall survival (P equal to 0.01). A TP53 co-mutation against wild-type TP53 gave 1.5 for progression-free survival and 1.6 for overall survival, both with P values below 0.001.

Both associations held in multivariable Cox regression after accounting for clinical covariates, which is the basis on which the authors call them independent predictors. The abstract names neither the covariates included nor the confidence intervals around any of the four hazard ratios, so the precision of each estimate cannot be read from it.

A database cohort of 606 patients, with a real-world progression endpoint

Patients were studied from a United States clinical-genomic database rather than enrolled in a trial, and the endpoints were real-world progression-free survival and overall survival determined by Kaplan-Meier methods. TP53 co-mutations were present in 384 of the 606 patients, or 63%, which makes the TP53-wildtype group the smaller of the two throughout the comparisons above.

The authors propose the combination of the two markers as a way of identifying patients for novel trials or for approved intensified therapies. That is a proposal about trial design and treatment selection rather than a demonstration that intensified treatment helps these patients, and this study tested no intensified regimen.

Sources

  1. Lung Cancer. The impact of EGFR subtype combined with TP53 co-mutation status on survival outcomes with front-line osimertinib in non-small cell lung cancer (NSCLC) (2026-08-01). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Hossein Borghaei.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

T. Newsom-DavisX. Le
Sep 26 2025
ILCS 2025
Targeted Therapies

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw
Sep 26 2025
ILCS 2025
Targeted Therapies

Targeting EGFR and ALK in NSCLC

} 26 min

T. John
Sep 26 2025
ILCS 2025
Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 12 2026
RESEARCH
BiomarkersResectable NSCLCTargeted Therapies

MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells

Z. Piotrowska
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 16 2026
RESEARCH
Advanced NSCLC

Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study

L. Bubendorf
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue

N. Girard